Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Hong Kong
· Delayed Price · Currency is HKD 5.70
-0.01 (-0.18%)
May 2, 2025, 4:08 PM HKT
HKG:1066 Revenue
In the year 2024, Shandong Weigao Group Medical Polymer Company had annual revenue of 13.09B CNY, down -1.08%. Shandong Weigao Group Medical Polymer Company had revenue of 6.45B in the half year ending December 31, 2024, a decrease of -3.26%.
Revenue
13.09B CNY
Revenue Growth
-1.08%
P/S Ratio
1.87
Revenue / Employee
1.03M CNY
Employees
12,719
Market Cap
26.02B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.09B | -142.38M | -1.08% |
| Dec 31, 2023 | 13.23B | -518.02M | -3.77% |
| Dec 31, 2022 | 13.75B | 538.53M | 4.08% |
| Dec 31, 2021 | 13.21B | 1.59B | 13.65% |
| Dec 31, 2020 | 11.62B | 1.24B | 11.93% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |